Description:

Ondansetron Injection USP 2mg/ml (Onsett 2ml by various manufacturers) is a sterile parenteral antiemetic medication used to prevent and treat nausea and vomiting. It is primarily indicated for:

• Chemotherapy-induced nausea and vomiting (CINV).
• Radiotherapy-induced nausea and vomiting.
• Postoperative nausea and vomiting (PONV).
• Severe nausea/vomiting in other settings (e.g., gastroenteritis, migraine, or hyperemesis gravidarum). It acts as a selective 5-HT3 receptor antagonist, blocking serotonin receptors in the vagus nerve and chemoreceptor trigger zone in the brain. In Ghana (Accra), it is a common prescription injectable used in hospitals, oncology units, surgical wards, and emergency departments for acute nausea control.

Prescription:

Prescription-only (requires a doctor’s prescription in Ghana; administered by healthcare professionals via IV or IM injection in hospitals/clinics; not for self-administration or OTC dispensing due to IV/IM route and need for monitoring in high-risk patients).

Therapeutic Category:

Antiemetic / 5-HT3 Receptor Antagonist (Selective serotonin 5-HT3 receptor blocker.

Active Ingredients/Composition:

• Active ingredient: Ondansetron (as ondansetron hydrochloride dihydrate) – 2 mg per ml (4 mg in 2 ml ampoule). Other ingredients: Sodium chloride (for isotonicity), citric acid monohydrate, sodium citrate dihydrate (pH buffering), water for injection. The solution is clear, colourless to pale yellow, sterile, and preservative-free.

Vitamins: None.

Minerals: None (trace sodium from sodium chloride, but not therapeutic).

Variant:

• Onsett 2mg/ml Injection 2ml (standard 2 ml ampoule containing 4 mg ondansetron). Related variants: Ondansetron 2mg/ml in 4ml ampoules (8 mg total), 8mg/4ml, or 16mg/8ml, oral ondansetron tablets/orodispersible films, or oral solution. The 2ml ampoule (4 mg dose) is the most common for single-dose IV/IM use.

Consume Type:

Injectable – Intravenous (IV) bolus (slow push) or infusion, Intramuscular (IM) injection (administered only by healthcare professionals).

Directions/Usage: Administered only in clinical settings.

• Adults (CINV): 8 mg IV slow push (over 2–5 minutes) or infusion 15–30 minutes before chemotherapy; may repeat 8 mg IV 8 hours later or 4–8 mg IV/IM every 8–12 hours as needed.
• PONV prophylaxis: 4 mg IV slow push at induction of anaesthesia.
• PONV treatment: 4 mg IV slow push.
• Children: Weight-based (0.1–0.15 mg/kg IV; max 4–8 mg/dose).
• Slow IV push (over at least 2–5 minutes) to avoid transient visual disturbances.
• Dilute for infusion if needed (compatible with 0.9% NaCl or 5% dextrose).
• Duration: Short-term (usually 1–3 days for acute nausea); switch to oral ondansetron when possible.

Common Side Effects: Common:

• Headache
• Flushing or warmth sensation.
• Constipation.
• Injection site reactions (pain, redness).
• Dizziness, fatigue. Rare/serious (seek immediate help): QT prolongation (arrhythmias – monitor ECG in high-risk patients), serotonin syndrome (if combined with serotonergic drugs), severe allergic reactions, or transient visual disturbances (blurred vision, temporary blindness – rare with rapid IV).

Package Type:

Glass ampoules of 2 ml (each containing 4 mg ondansetron; packs of 5 or 10 ampoules; labelled carton with instructions and warnings).

Storage Advice: Store at room temperature (below 25–30°C) in original packaging, protected from light. Do not freeze. Keep out of reach of children.

Safety Advice:

• Administered only under medical supervision (risk of QT prolongation – monitor ECG in patients with cardiac risk factors or on QT-prolonging drugs).
• Contraindicated in hypersensitivity to ondansetron, apomorphine (risk of profound hypotension), or congenital long QT syndrome.
• Caution in patients with electrolyte abnormalities (hypokalaemia/hypomagnesemia increase QT risk), hepatic impairment (dose adjustment), or on serotonergic drugs (e.g., SSRIs – serotonin syndrome risk).
• Slow IV administration required (rapid push may cause transient visual changes or dizziness).
• If severe headache, chest pain, palpitations, or allergic symptoms occur, stop use and seek urgent care.
• Keep out of reach of children (overdose risk).

Product Substitutes: Similar ondansetron 2mg/ml injections in Ghana include:

• Generic ondansetron 2mg/ml injection (various importers).
• Zofran IV (original GSK brand if stocked).
• Emeset, Onsat, or other local generics. Alternatives: Granisetron IV, palonosetron IV (longer-acting 5-HT3 antagonists), metoclopramide IV, or dexamethasone IV (often combined for CINV/PONV). Consult doctor/pharmacist in Accra (e.g., hospital pharmacy) for alternatives.

Manufacturer/Marketer:

Varies by exact batch (Ondansetron 2mg/ml injections often by Indian manufacturers like Neon Laboratories, Samarth Life Sciences, or local Ghanaian producers for generics). Marketed/distributed in Ghana by local importers/pharmacies (widely stocked in hospital pharmacies).

Country of Origin:

India (primary source for generic ondansetron 2mg/ml injections imported to Ghana; BP/USP-compliant generics common in African markets).